KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Current Deferred Revenue (2017 - 2025)

Neogenomics' Current Deferred Revenue history spans 9 years, with the latest figure at $851000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 14.23% year-over-year to $851000.0; the TTM value through Dec 2025 reached $851000.0, up 14.23%, while the annual FY2025 figure was $851000.0, 14.23% up from the prior year.
  • Current Deferred Revenue reached $851000.0 in Q4 2025 per NEO's latest filing, down from $2.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $7.6 million in Q4 2022 to a low of $745000.0 in Q4 2024.
  • Average Current Deferred Revenue over 5 years is $3.8 million, with a median of $3.8 million recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: crashed 81.14% in 2024, then soared 111.47% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $6.1 million in 2021, then rose by 23.7% to $7.6 million in 2022, then plummeted by 71.81% to $2.1 million in 2023, then crashed by 65.02% to $745000.0 in 2024, then grew by 14.23% to $851000.0 in 2025.
  • Per Business Quant, the three most recent readings for NEO's Current Deferred Revenue are $851000.0 (Q4 2025), $2.1 million (Q3 2025), and $1.5 million (Q2 2025).